A novel method in order to evaluate the efficacies and the safeties of new drugs for hepatocellular carcinoma with loss of transforming growth factor-β signaling
✍ Scribed by Hisashi Moriguchi
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 56 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
positive and negative predictive values of the original model using transient elastography alone were 72.4% and 96.6%, respectively. 1 Because the addition of FIB-4 could not significantly improve the performance of LSM to exclude advanced fibrosis, its major role is probably a confirmatory test for advanced fibrosis as suggested by transient elastography. If liver biopsy was performed in all patients with LSM Ͼ7.9 kPa, 98 (39.8%) patients of the entire cohort required the procedure. If liver biopsy was performed only in patients with discordant transient elastography and FIB-4 index when LSM is Ͼ9.6 kPa, 85 (34.6%) patients required the procedure (Fig. ). Other new noninvasive tests, such as Fibrometer, could be useful in combination with LSM and have to be evaluated in these patients. 5 In conclusion, transient elastography alone has good negative predictive value in excluding advanced fibrosis and cirrhosis in patients NAFLD. The main role of combined noninvasive tests would be to increase the positive predictive value in diagnosing advanced disease. This can be achieved when more specific biomarkers of liver fibrosis are identified in the future.